| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
110,820,000 |
| Market
Cap: |
1.18(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.58 - $25.88 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Precision Biosciences is a clinical stage gene editing company focused on improving life by developing ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases with the application of its wholly owned proprietary ARCUS genome editing platform. Co. is simultaneously conducting a Phase 1/2a clinical trial evaluating PBCAR0191 as a potential first-in-class and a Phase 1 clinical trial evaluating PBCAR19B as, if approved, a potential CD19-targeting CAR T cell therapies in adult patients with relapsed or refractory, B-cell malignancies.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
90,000 |
189,021 |
| Total Buy Value |
$0 |
$0 |
$43,200 |
$170,792 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
2,480 |
210,683 |
365,092 |
452,513 |
| Total Sell Value |
$25,523 |
$100,755 |
$167,195 |
$249,561 |
| Total People Sold |
4 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
9 |
12 |
17 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Amoroso Michael |
President and CEO |
• • – |
2023-03-22 |
4 |
AS |
$0.82 |
$38,539 |
D/D |
(46,999) |
68,738 |
|
-27% |
|
| Amoroso Michael |
President and CEO |
• • – |
2023-03-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
102,535 |
115,737 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2023-03-17 |
4 |
B |
$0.86 |
$17,200 |
D/D |
20,000 |
245,614 |
2.74 |
-35% |
|
| List Alan |
Chief Medical Officer |
• – – |
2023-03-06 |
4 |
AS |
$1.07 |
$10,136 |
D/D |
(9,473) |
38,240 |
|
-36% |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2023-03-06 |
4 |
AS |
$1.07 |
$13,024 |
D/D |
(12,172) |
50,063 |
|
-36% |
|
| List Alan |
Chief Medical Officer |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,453 |
47,713 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,576 |
1,930,207 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
51,071 |
225,614 |
|
- |
|
| Barton Shane |
VP & Corporate Controller |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,722 |
21,422 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2023-03-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,558 |
62,235 |
|
- |
|
| Smith J. Jefferson |
Chief Research Officer |
• – – |
2023-02-28 |
4 |
A |
$0.95 |
$11,549 |
D/D |
12,157 |
1,914,631 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2023-02-28 |
4 |
A |
$0.95 |
$11,025 |
D/D |
11,605 |
174,543 |
|
- |
|
| Scimeca Dario |
General Counsel and Secretary |
• – – |
2023-02-28 |
4 |
A |
$0.95 |
$2,055 |
D/D |
2,163 |
34,677 |
|
- |
|
| Amoroso Michael |
President and CEO |
• • – |
2022-10-17 |
4 |
AS |
$1.32 |
$14,528 |
D/D |
(11,006) |
13,202 |
|
-19% |
|
| Amoroso Michael |
President and CEO |
• • – |
2022-10-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
24,208 |
24,208 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2022-09-23 |
4 |
B |
$1.23 |
$10,086 |
D/D |
8,200 |
162,938 |
2.74 |
-1% |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2022-09-22 |
4 |
B |
$1.34 |
$49,630 |
D/D |
37,037 |
154,738 |
2.74 |
-4% |
|
| Smith J. Jefferson |
Chief Research OfficerOfficer |
• – – |
2022-09-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
237,959 |
|
-13% |
|
| Smith J. Jefferson |
Chief Research OfficerOfficer |
• – – |
2022-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,902,474 |
|
-13% |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2022-06-22 |
4 |
B |
$1.50 |
$50,676 |
D/D |
33,784 |
117,701 |
2.74 |
-5% |
|
| Novartis Ag |
10% Owner |
– – • |
2022-06-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,407,440 |
|
18% |
|
| List Alan |
Chief Medical Officer |
• – – |
2022-04-27 |
4 |
AS |
$2.10 |
$16,328 |
D/D |
(7,775) |
18,260 |
|
-24% |
|
| List Alan |
Chief Medical Officer |
• – – |
2022-04-26 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,035 |
26,035 |
|
- |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2022-03-17 |
4 |
B |
$3.08 |
$51,365 |
D/D |
16,677 |
36,189 |
2.74 |
-54% |
|
| Kelly John Alexander |
Chief Financial Officer |
• – – |
2022-02-28 |
4 |
A |
$3.61 |
$9,798 |
D/D |
2,714 |
19,512 |
|
- |
|
179 Records found
|
|
Page 3 of 8 |
|
|
0.29 (2.65%) 
